دورية أكاديمية
أعرض في EDS

Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy.

التفاصيل البيبلوغرافية
العنوان: Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy.
المؤلفون: Li Y; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.; School of Life Science, Jilin University, Changchun 130012, P. R. China., Ding J; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States., Xu X; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, P. R. China., Shi R; Department of Radiation Oncology, University Hospital, LMU Munich, Munich 81379, Germany., Saw PE; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, P. R. China., Wang J; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States., Chung S; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States., Li W; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States., Aljaeid BM; King Abdulaziz University, Jeddah 21589, Saudi Arabia., Lee RJ; School of Life Science, Jilin University, Changchun 130012, P. R. China.; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States., Tao W; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States., Teng L; School of Life Science, Jilin University, Changchun 130012, P. R. China., Farokhzad OC; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States., Shi J; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
المصدر: Nano letters [Nano Lett] 2020 Jul 08; Vol. 20 (7), pp. 4857-4863. Date of Electronic Publication: 2020 Jun 08.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101088070 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-6992 (Electronic) Linking ISSN: 15306984 NLM ISO Abbreviation: Nano Lett Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Chemical Society, c2001-
مواضيع طبية MeSH: Nanoparticles* , Neoplasms*/drug therapy , Neoplasms*/genetics, Cell Line, Tumor ; Drug Delivery Systems ; Humans ; Hypoxia ; Nanomedicine ; RNA Interference ; RNA, Small Interfering/genetics
مستخلص: As a hallmark of solid tumors, hypoxia promotes tumor growth, metastasis, and therapeutic resistance by regulating the expression of hypoxia-related genes. Hypoxia also represents a tumor-specific stimulus that has been exploited for the development of bioreductive prodrugs and advanced drug delivery systems. Cell division cycle 20 (CDC20) functions as an oncogene in tumorigenesis, and we demonstrated the significant upregulation of CDC20 mRNA in the tumor vs paratumor tissues of breast cancer patients and its positive correlation with tumor hypoxia. Herein, a hypoxia-responsive nanoparticle (HRNP) was developed by self-assembly of the 2-nitroimidazole-modified polypeptide and cationic lipid-like compound for delivery of siRNA to specifically target CDC20, a hypoxia-related protumorigenic gene, in breast cancer therapy. The delivery of siCDC20 by HRNPs sufficiently silenced the expression of CDC20 and exhibited potent antitumor efficacy. We expect that this strategy of targeting hypoxia-correlated protumorigenic genes by hypoxia-responsive RNAi nanoparticles may provide a promising approach in cancer therapy.
References: Biomaterials. 2014 Feb;35(5):1735-43. (PMID: 24290696)
Int J Biol Macromol. 2018 Apr 15;110:399-405. (PMID: 29133095)
Adv Healthc Mater. 2018 Feb;7(4):. (PMID: 29227047)
Oncogene. 2008 Mar 6;27(11):1562-71. (PMID: 17873905)
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8260-5. (PMID: 26100900)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Adv Mater. 2016 May;28(17):3313-20. (PMID: 26948067)
Pharmacol Ther. 2015 Jul;151:141-51. (PMID: 25850036)
Oncogene. 2003 Sep 1;22(37):5907-14. (PMID: 12947397)
BJU Int. 2010 Jan;105(1):8-13. (PMID: 19889065)
Dev Cell. 2014 May 27;29(4):377-91. (PMID: 24871945)
Nature. 2014 Oct 30;514(7524):646-9. (PMID: 25156254)
Br J Cancer. 2014 Jun 10;110(12):2905-13. (PMID: 24853182)
Acta Biomater. 2016 Oct 15;44:341-54. (PMID: 27545812)
Nat Rev Cancer. 2002 Jan;2(1):38-47. (PMID: 11902584)
Nano Lett. 2017 Jul 12;17(7):4427-4435. (PMID: 28636389)
Nat Genet. 2003 Jul;34(3):267-73. (PMID: 12808457)
Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1510-1513. (PMID: 29276823)
Oncogenesis. 2018 Jan 24;7(1):10. (PMID: 29362402)
Chem Commun (Camb). 2016 Jun 30;52(55):8492-500. (PMID: 27225824)
Curr Pharm Des. 2013;19(18):3210-4. (PMID: 23151139)
Cancer Cell. 2010 Dec 14;18(6):641-54. (PMID: 21156286)
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18638-43. (PMID: 24167294)
Angew Chem Int Ed Engl. 2014 Mar 24;53(13):3362-6. (PMID: 24554550)
Nat Rev Cancer. 2011 Jun;11(6):393-410. (PMID: 21606941)
Cell Death Differ. 2008 Apr;15(4):678-85. (PMID: 18259193)
Oncogene. 2010 Feb 4;29(5):625-34. (PMID: 19946328)
معلومات مُعتمدة: R01 CA200900 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: CDC20; RNA interference; cancer therapy; gene silencing; hypoxia; polypeptide nanoparticle
المشرفين على المادة: 0 (RNA, Small Interfering)
تواريخ الأحداث: Date Created: 20200602 Date Completed: 20210624 Latest Revision: 20210709
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7405292
DOI: 10.1021/acs.nanolett.0c00757
PMID: 32479088
قاعدة البيانات: MEDLINE
الوصف
تدمد:1530-6992
DOI:10.1021/acs.nanolett.0c00757